NeoGenomics Sees FY23 Revenue Of $565M-$575M (Prior View $555M-$565M); Sees Net Loss Of $(107)M-$(100)M
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics has updated its FY23 revenue forecast to $565M-$575M, up from the previous estimate of $555M-$565M. However, the company also predicts a net loss of $107M-$100M.
August 08, 2023 | 11:27 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NeoGenomics has raised its FY23 revenue forecast, which could be seen as a positive sign by investors. However, the projected net loss might offset this optimism.
The raised revenue forecast indicates that NeoGenomics expects to perform better than previously thought, which could boost investor confidence and potentially drive the stock price up. However, the projected net loss could dampen this optimism and cause some investors to sell, potentially driving the stock price down. The net effect on the stock price is uncertain, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100